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Accepted 10 July 2017; Published online 14 July 2017AbstractPragmatic trials can improve our understanding of how treatments will perform in routine practice. In a series of eight papers, the
GetReal Consortium has evaluated the challenges in designing and conducting pragmatic trials and their specific methodological, opera-
tional, regulatory, and ethical implications. The present final paper of the series discusses the operational and methodological challenges
of data collection in pragmatic trials. A more pragmatic data collection needs to balance the delivery of highly accurate and complete data
with minimizing the level of interference that data entry and verification induce with clinical practice. Furthermore, it should allow for the
involvement of a representative sample of practices, physicians, and patients who prescribe/receive treatment in routine care. This paper
discusses challenges that are related to the different methods of data collection and presents potential solutions where possible. No
one-size-fits-all recommendation can be given for the collection of data in pragmatic trials, although in general the application of existing
routinely used data-collection systems and processes seems to best suit the pragmatic approach. However, data access and privacy, the time
points of data collection, the level of detail in the data, and the lack of a clear understanding of the data-collection process were identified as
main challenges for the usage of routinely collected data in pragmatic trials. A first step should be to determine to what extent existing
health care databases provide the necessary study data and can accommodate data collection and management. When more elaborate or
detailed data collection or more structured follow-up is required, data collection in a pragmatic trial will have to be tailor-made, often using
a hybrid approach using a dedicated electronic case report form (eCRF). In this case, the eCRF should be kept as simple as possible to
reduce the burden for practitioners and minimize influence on routine clinical practice.  2017 The Authors. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction traditional, explanatory trials deliver data on efficacy andClinical trials that evaluate new drug treatments are
required to underpin market authorization and are generally
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licenses/by-nc-nd/4.0/).safety of treatments, yet they often insufficiently inform
physicians, policy makers, and other stakeholders how
treatments will actually perform in real-world clinical
practice [1]. Pragmatic trials, however, evaluate relative
effectiveness under conditions routinely encountered in
clinical practice and can yield evidence of the added value
of new treatments in real life [2].
Clinical trials commonly require the collection of highly
detailed patient data. This necessitates onsite staff training
regarding data collection and management, which presents
a burden to study sites, interferes with usual care, and ofteness article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 There is a need for more pragmatically designed
clinical trials to evaluate real-life treatment effects
in routine clinical practice in an earlier phase in the
drug development process.
 In general, the use of electronic case report forms
(eCRFs) for data collection, in the way they are
currently being used in most clinical trials, inter-
feres with routine clinical practice. This may lead
to the inclusion of a nonrepresentative sample of
patients, physicians, and practices and therefore
affect the generalizability of the trial results. As
such their suitability for pragmatic trials is
questionable.
What this adds to what was known?
 This paper addresses challenges and solutions for
data collection and management in pragmatic tri-
als, where a high level of accuracy and complete-
ness of data needs to be balanced with a low
level of interference with clinical practice.
 Data access and privacy, the time points of data
collection, the level of detail in the data, and the
lack of a clear understanding of the data-collection
process were identified as main challenges for the
usage of routinely collected data, for example, elec-
tronic health records, in pragmatic trials.
 Current international initiatives, that might facili-
tate a more pragmatic approach for data collection
and management, are discussed.
What is the implication and what should change
now?
 The quality of routinely collected data can be opti-
mized by, for example, automated query genera-
tion and pop-ups that are embedded in the
electronic health record or other electronic health
care systems.
 Pragmatic trials should interfere with routine care as
little as possible while ensuring high-quality data.
Successful existing pragmatic trials typically use a
hybrid approach for data collection: dedicated
eCRFs combined with routinely collected data.
excludes research-na€ıve practitioners and sites from partic-
ipation in such trials [3,4]. This does not affect the aim of
more explanatory trials, where the interest is in the pharma-
cological effect of the drug. However, it may limit the
generalizability of the study results and thus the value of
14 A.-K. Meinecke et al. / Journal of Cevidence of a pragmatic trial. Therefore, pragmatic trials
need to closely align all study-related interventions with
routine clinical practice, to minimize interference with
routine care and enhance the generalizability of the results
to the real-word setting [1], while simultaneously ensuring
high-quality data.
This paper identifies existing methods for the collection
of data and their suitability for pragmatic trials, discusses
their respective methodological and operational challenges,
suggests possible solutions, and identifies opportunities and
developments in this field (Box 1).2. Methodological choices on data collection for
pragmatic trials
The decision on the most suitable method for data
collection in pragmatic trials should be based on several
considerations, of which the most important ones are
described in the following sections.2.1. Data-collection methods
In general, three approaches for data collection in trials
can be identified:
i. Collecting all necessary data using electronic case
report forms (eCRFs) that are specifically created
for the study. This is the usual method for traditional
more explanatory trials. This approach is the most
likely to interfere with routine practice, as additional
labor and expertise is often required to implement
the data-collection process.
ii. Extracting routinely collected data from existing sour-
ces, such as electronic health records (EHRs: systems
into which practitioners enter routine clinical and
laboratory data during usual practice), registries (any
system that collects uniform data), or insurance claims
(databases maintained by payers for reimbursement
purposes or other routine health care databases). This
approach does not interfere with routine practice as it
does not require additional data collection.
iii. Combining routinely collected data with additional
data collected specifically for the study in a hybrid
approach.
Which data are required, the level of detail needed, as
well as the frequency and timing of collection drive the
choice for the method of data collection. Although large
numbers of variables are usually collected at predefined
time points in an explanatory trial, the data collection in
a pragmatic trial would ideally follow real-life clinical
practice: that is, data, with the level of detail needed for
treating the patient, are collected when patients have
contact with their health care provider, who then routinely
enters it into his/her health-record system. To find the right
balance between the highly controlled data collection in
Box 1 Series on pragmatic trials
Pragmatic trials aim to generate real-world evi-
dence on the (relative) effects of treatments, general-
izable to routine practice. In this series, we will
discuss options and choices for pragmatic trial
design, operational consequences, and the interpreta-
tion of results.
1. Introduction
2. Setting, sites, and investigator selection
3. Patient selection challenges and consequences
4. Informed consent
5. Usual care and real life comparators
6. Outcome measures in the real world
7. Safety, quality and monitoring
8. Data collection and management
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data collection (eg, EHRs) remains a challenge when
designing a pragmatic trial (Fig. 1). Using a hybrid
approach, as generally used in existing pragmatic trials,
where ‘‘traditional’’ methods (ie, eCRFs) are used in a
limited manner and combined with direct use of routinely
collected data may provide a good balance between data
quality and interference with routine clinical practice
(Boxes 2 and 3) [5,6].
2.2. Quality of data collection
Other aspects of data collection that need to be considered
and decided on when designing a pragmatic trial are (1) the
extent to which onsite staff will be trained in data collection,
(2) the extent of quality checks implemented in the entry
system, both directly and remotely, (3) other measures to
minimize data-entry errors. The advantages in terms of
improved data quality need to be weighed against the
possible disadvantage of reducing generalizability because
of changed routine practice. Of note, regulatory authorities
and ethics committees may demand training on data collec-
tion and methods for quality checking [7,8].
3. Operational challenges of data collection and
possible solutions
A number of operational challenges can be identified for
the different approaches for data collection in more prag-
matic trials.
3.1. Challenges with eCRF-based data collection
eCRFs are the most-used tool in more traditional
explanatory trials. Their great advantage is that they allow
the definition and collection of the exact data required at
distinct times (Table 1). Because of the fact that the data
are specifically collected for the research purpose, usuallyFig. 1. In a pragmatic trial, the aim is to generate high-quality data
and simultaneously interfere with routine care as little as possible.
eCRF, electronic case report form; EHR, electronic health record.collected by trained staff, and typically monitored and vali-
dated closely, there is a general perception that this method
delivers high-quality, valid data. Nevertheless, data collected
by eCRFs also have quality issues, such as entry errors or
transcription errors from paper source [9]. Moreover, this
method of data collection typically cannot be implemented
without at least some interference in routine care. Because
of an increase in workload that is generally associated with
this approach, the conditions necessary for using eCRFs may
often only be fulfilled at specialized sites that have the exper-
tise and manpower to meet all requirements. When detailed
data collection is required on top of the usual workload,
general practitioners or smaller hospitals, which often treat
the patient population of interest, may not be able to cope
with this approach [5,10]. In addition, (extensive) staff
training in the use of data-collection systems as well as
changes in data handling as such may influence routine
clinical practice due to the Hawthorne effect [3]. Both might
limit the generalizability of the results of a trial. To reduce
the burden for practitioners and to interfere with routine
clinical practice as little as possible, in pragmatic trials,
the eCRF and its implementation should be kept as simple
as possible [11]. Moreover, any additional interference, such
as onsite staff training and different approaches to minimize
and control for data-entry errors, should be kept as small as
possible. In addition, one should consider to what extent the
required information can be obtained from other systems.
3.2. Challenges with routinely collected data
The advantage of using routinely collected data in a
pragmatic trial is that data collection does not or only
minimally interfere with usual care (Table 1). Another
advantage of standard electronic systems, especially EHRs,
might be that they allow access to numerous variables that
were not included in the trial protocol, which nevertheless
Box 2 eLung/Retroprodpragmatic trials using EHRs in combination with add-on systems
Aim: To develop and evaluate methods to implement simple pragmatic trials using routinely collected electronic
health records (EHRs) and recruiting patients at the point of care; to identify the barriers and facilitators for general
practitioners (GPs) and patients and the experiences of trial participants.
Outcomes: Successful trial completion with implementation of information technology (IT) system for flagging and
data processing and documentation of operational and scientific experiences
Approach for data collection:
 Trials were conducted in English and Scottish general practices that contributed their EHRs to a research database
(including a total of 459 practices).
 Additional software was developed that allowed for instantaneous monitoring of EHR activities, flagging and clini-
cian’s notification during consultation of trial eligibility, complex eligibility assessments using the EHR database,
daily eligibility review, confirmation of eligibility and randomization on the study web site, daily monitoring of side
effects, and long-term follow-up of major clinical outcomes.
 Recruitment of patients was done by general practitioners (GPs) via invitations (i.e., cold recruitment) and/or imme-
diate flagging (through the HER system) while unscheduled consultation (i.e., hot recruitment).
 GPs were required to complete Web-based protocol and good clinical practice training and required governance ap-
provals were obtained for both trials.
 Potentially eligible patients were identified through the EHR; however, GPs had to confirm eligibility and patients
were then randomized using a concealed allocation schedule.
 Neither patients nor clinicians were blinded.
 Central data monitoring was used, and site visits by research staff were not intended but partially conducted when IT/
software issues occurred.
Reference: van Staa et al. The opportunities and challenges of pragmatic point-of-care randomized trials using
routinely collected electronic records: evaluations of two exemplar trials. HTA 2014; 18(43).
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information, for example, in the context of modification
of treatment effects. However, using routinely collected
data may lead to a number of challenges that need to be
considered when designing a pragmatic trial as described
in the following [12].3.2.1. Routinely collected data are not meant for
research purposes
Systems that collect patient data in routine daily care
include EHRs, insurance claims, as well as other health
care or vital statistics databases and registries. EHRs are
systems in which practitioners enter routine clinical and
laboratory data of their patients over the course of their
usual practice. Because the primary focus of such data is
the support of clinical care rather than research, data may
lack detailed information on indications, patient character-
istics, treatments, and events and may be less structured, for
example only provided as free text [5,12,13]. Claims data-
bases are run by insurers or other payers for reimbursement
purposes and may contain information on the diagnoses,
procedures, national drug codes, service provider, prescrib-
ing physicians, or health plans. This information is usually
entered in a structured, coded format, but it may not be very
detailed. Consequently, claims databases often lack
information on relevant clinical variables and patient char-
acteristics, and often the information will not be timely[12e14]. There is a trend though among database owners
of claims data, especially in the United States, to increase
the number of clinical variables to make the databases us-
able for scientific research purposes (eg, Optum) [15].3.2.2. Generation of valid, accurate, and complete data
may be challenging
A major challenge when using routinely collected data is
to produce valid, accurate results [12,16]. As data
collection happens under real-life conditions, measurement
may be more variable and higher levels of missing data and
entry errors may be expected, possibly resulting in bias
especially, but not only, when measurement error is not
random [17,18]. Such bias can call into question the valid-
ity of a trial, especially if this ascertainment differs across
comparison groups, for example, when physicians suspect
an effect on blood pressure of a new treatment, data on
blood pressure may be collected more frequent and uniform
for that trial arm. In case data are likely to be missing at
random, the problem may be overcome by appropriate
statistical methods such as multiple imputation [19].
Random errors in data collection and missing data can
reduce the power of the study, with implications for the
calculation of the required sample size. Gauging the pros
and cons of using statistical approaches to deal with the
limitations of routinely collected data vs. the implementa-
tion of additional data collection is difficult to evaluate
Box 4 TASTEda pragmatic trial nested in an existing registry
Aim: To evaluate the effects of thrombus aspiration in patients with ST-elevation myocardial infarction undergoing a
primary percutaneous coronary intervention
Outcomes: All-cause mortality (primary), coronary re-interventions, and outcomes related to the intervention
Approach for data collection:
 The trial was embedded in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
a. the registry is fully embedded in daily clinical practice with case report forms implemented electronically and
Web-based data entry
b. included all 29 Swedish centers performing coronary angiography and interventions
c. collects detailed information about coronary interventions over time
d. linked to the Swedish National Population Registry including personal data and deaths
e. regular source data verification on randomly sampled centers/variables.
 Randomization for the trial was directly implemented in the eCRFs of the registry, and all outcomes of the trial were
based on data routinely collected within the registry
 Due to this approach, the trial could be performed without disruption of usual practice, only informed consent and
randomization deviated from routine practice.
Reference: Frobert O. et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med
2013; 369: 1587-97.
Box 3 Salford Lung Studyda pragmatic trial using EHRs in combination with add-on systems
Aim: The Salford Lung Study (SLS) is the world’s first pragmatic RCT (pRCT) of an investigational medication.
SLS will evaluate the effectiveness and safety of a new inhaled medicine combination compared with patients’ usual
care in a broad group of COPD patients in an everyday clinical practice setting. The study is being conducted in and
around Salford, UK.
Approach for data collection:
 The SLS uses Salford’s electronic health records (EHRs) systems and is delivered in collaboration with local health
care providers to allow patients on the study to be closely monitored in real time, but with minimal intrusion into
their everyday lives.
 The study’s principal investigators are the GPs. They are ideally placed to facilitate recruitment, identify, and report
SAEs or serious ADRs and report study end points. GPs may make treatment adjustments according to their clinical
opinion. Repeat prescriptions of study medication are issued by GPs as usual and collected by patients from their
usual pharmacy.
 Pharmacy data were initially collected by faxing copies of study treatment prescriptions to the study coordination
center, but these are now collected electronically. Prescription collection data are used to assess treatment adherence.
 Hospital admissions are primarily to two local hospitals, Salford Royal Hospital and the University Hospital of South
Manchester. Relevant admissions are identified electronically and assessed by a separate safety team.
 The integrated system was set up by NorthWest EHealth, a not-for-profit organization formed by a partnership be-
tween The University of Manchester, Salford Royal Foundation Trust and Salford Clinical Commissioning Group,
and links patients’ records across their GP surgeries and hospitals. This removes the need for the enforced interven-
tions and controls required in RCTs which may affect the way a patient behavesdfor example, how and when they
take their medication.
References: The Salford Lung Study protocol: a pragmatic, randomized phase III real-world effectiveness trial in
chronic obstructive pulmonary disease.
Nawar Diar Bakerly, Ashley Woodcock, John P. New, J. Martin Gibson, Wei Wu, David Leather and Jørgen Vestbo.
Respiratory Research 2015;16:101 http://dx.doi.org/10.1186/s12931-015-0267-6.
Clinical trials meet the real worlddhttps://www.gsk.com/en-gb/behind-the-science/patients-and-consumers/clinical-
trials-meet-the-real-world/
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Box 5 SCOTda pragmatic trial using record linkage for identifying potential outcome events
Aim: To evaluate the cardiovascular (primary) and gastrointestinal (secondary) safety of celecoxib vs. traditional
nonsteroidal anti-inflammatory drug therapy in patients with osteoarthritis or rheumatoid arthritis.
Outcomes: First hospitalization for nonfatal myocardial infarction or nonfatal stroke or cardiovascular death. Other
outcomes were hospitalization or death for various reasons (gastrointestinal, specific cardiovascular, and renal)
Approach for data collection:
 Participants were recruited in general practices (Scotland, England, Denmark, and Netherlands) and randomized by
telephone or a web site.
 Outcome events were not directly collected during follow-up but potential events identified through record linkage:
the trial database was linked every 3 months to national population health care and mortality databases containing all
hospital discharge diagnoses or causes of death in a particular country.
 For each potential outcome event, original case records were requested. Each potential event was adjudicated by a
blinded, independent adjudication committee.
 Serious adverse events were recorded in the electronic case report form.
Reference: MacDonald TM et al. Methodology of a large prospective, randomized, open, blinded end point stream-
lined safety study of celecoxib vs. traditional nonsteroidal anti-inflammatory drugs in patients with osteoarthritis or
rheumatoid arthritis: protocol of the standard care vs. celecoxib outcome trial (SCOT). BMJ open 2013; 3: e002295.
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be easy to assess the influence of errors a priori, and this
may need a separate feasibility study. The evaluation of
measurement of outcomes for pragmatic trials as performed
in practice and measures on how to improve this, both
important components of feasibility studies, are addressed
elsewhere in this series [21].
Training staff in the use of a routine data-collection
system might solve or alleviate the problem of incorrect
or incomplete data entry. However, training staff may
change more than data entry alone: training causes interfer-
ence, which might have an impact on behavior in general
(Hawthorne effect) [3]. Furthermore, it might lead to
changes in treatment, if training relates to information
relevant for treatment decisions and thus interfere with
the usual care provided to patients, possibly resulting in a
decrease in the generalizability of trial results [1].
Another option that might interfere less with clinical
routine would be to implement data quality checks in the
system that would detect incorrect or missing data during
data entry, and specify procedures for correction. When a
health care database is the source of study data, any change
made to the database after data extraction needs to be
captured in an audit trail [22,23].3.2.3. Quality and completeness of data varies within
and among databases
The collected data as such and their level of detail,
completeness, and correctness can vary, both within and
between existing databases [13,16].
Generally, ‘‘completeness’’ of data in health care data-
bases depends on what data exactly are routinely collected
in health records and the exact data needs for a trial, and
one should be explicit about both when establishing theappropriateness of health care databases as a data source
for a pragmatic trial [24]. In addition, before selecting a
data-collection approach solely based on routinely
collected data, one needs a very good understanding of
the process of data entry and management in the individual
database [25] as well as of the database landscape within
and across settings and countries in which a pragmatic trial
will be performed [26]. As a starting point for finding the
optimal database for ones demands, the International
Society for Pharmacoeconomics and Outcomes Research
provides an international digest of databases [27]. This list
is neither exhaustive nor does it assess the quality,
completeness, and accessibility of data and its potential
for customization for a specific study, which would assist
the assessment of the suitability of data for inclusion in
pragmatic trials. However, guidelines exist for how to select
a database for a study, which are yet oriented toward non-
interventional studies [28]. The Medicines & Healthcare
products Regulatory Agency has recently published a posi-
tion paper in which compliance issues of EHRs are identi-
fied and user requirements for EHR owners are formulated
to ensure good clinical practice compliance [29]. It
provides a number of explicit recommendations, such as
‘‘Audit trails for information added to the EHR. Any new
information added to the subjects’ medical notes (whether
paper or electronic) should show when the entry was made
and by whom, so that the documentation provides a full
audit trial of events (any amendments/deletions etc.).’’ This
paper might be used as a basis for quality checks of EHRs.3.2.4. Compliance with safety requirements on adverse
event reporting
As described previously, routine data are typically
collected infrequently or irregularly, which poses problems
Table 1. Approaches for data collection for pragmatic trials with their potential (dis)advantages
Considerations for data collection Use of eCRF solely
Extraction of routinely collected
data Use of hybrid approach
Interference with routine
clinical practice/ limits
generalizability of results
May exclude sites from
participating due to extra
workload and change routine
clinical practice, depending on
how comprehensive the
additional workflow will be.
Does not change routine clinical
practice
Depends on
i. how extensive the additional
data collection is
ii. how well data validation checks
are already implemented in ex-
isting system
iii. how comprehensive the addi-
tional workflow will be
Time points of data collection Usually optimized to meet study
needs but could also be aligned
with routine practice
Dictated by routine clinical
practice
Can be optimized to meet study
needs but could also be aligned
with routine practice
Level of detail and quality
of the data
Level of detail is optimized for the
study. In general, high-quality
valid data, but entry/
transcription errors, may occur
Data are not collected for research
purposes and may be more
variable, display more missing
data and entry errors (both
random and systematic) may be
expected. Level of detail might
be insufficient for trial
In between eCRF and the approach
of using routinely collected data
depending on specific approach
All relevant variables
collected
Yes as eCRF is made specifically
for the study
Possibly not. However, one
advantage is that variables that
are not collected as part of the
trial but are relevant in hindsight
might be present in the
database
Probably yes as the hybrid
approach is designed to obtain
sufficient quality data on all
relevant variables for the study,
making use of routinely
collected data as much as
possible.
Compliance with safety
requirementsdreporting
of adverse event
Yes Possibly not
i. data are collected only at
routine contact moments be-
tween patient and care provider,
which may occur infrequent to
collect sufficient data on safety
ii. data extraction may often not
be in real time, as such
mandatory timelines for safety
reporting may not be met
Probably yes: safety requirements
may necessitate
i. the implementation of extra
data collection when frequency
of patient visits is too low or if
data collected are not sufficient
ii. an adjustment in the frequency
of data extraction or upload
from EHR if the routine system
is not sufficient
Data privacy and access Not an issuedonly study-specific
data are collected in line with
informed consent for the study.
Access to routinely collected
data(base) gives access to data
beyond what is required for a
study which introduces an
ethical challenge.
Access to routinely collected
data(base) gives access to data
beyond what is required for a
study which introduces an
ethical challenge.
Abbreviations: eCRF, electronic case report form; EHR, electronic health record.
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which frequent or regular scheduled visits may be deemed
necessary. Especially delays in recording data in relevant
databases and time between data entry and information
becoming available to the sponsor/in the study database
can interfere with obligatory timelines for reporting AEs
as well as result in missing data. This can adversely influ-
ence the validity of the study and raise safety issues
[7,30]. Calling patients after a defined time frame without
GP interaction might be a valid approach of ensuring the
assessment of AEs while keeping interference limited [6].
3.2.5. Data privacy and access
A further challenge with using routinely collected data is
protection of the privacy and confidentiality of research par-
ticipants [12]. Providing access to a health care databasesystem and therefore to patient data beyond what is required
for a study, as opposed to recording and accessing study-
specific data in an eCRF raises right-to-privacy concerns
[31]. In a recent series of papers exploring ethical issues in
pragmatic trials, McGraw et al. point out that patients have
concerns about privacy protection and may engage in ‘‘pri-
vacy-protecting behavior’’ such as withholding information
to health care providers. The authors argue that neither
privacy nor the value of pragmatic trials should be ‘‘compro-
mised for the sake of the other’’ [32]. Traditionally, anonym-
ity and informed consent have protected patient information,
but it has been argued that neither can ensure privacy in the
era of big data [32,33]. Technological solutions are sought
to fill the protection gap, but it is unlikely that these solutions
will defeat all challenges. To allow the use of personal data,
modifications of informed consent procedures have been
20 A.-K. Meinecke et al. / Journal of Clinical Epidemiology 91 (2017) 13e22proposed [34]. The concept of a learning health care system
also has emerged in which knowledge generation is ‘‘a
natural outgrowth and product of the health care delivery pro-
cess’’ [35]. In such a system, accessing patient data for
research purposes is likely to be facilitated. However, because
a tradeoff between utility and security remains and guidance
on how to balance privacy and research interests is currently
lacking, a small risk of identification might remain [36].
Privacy concerns inevitably constrain access to data by
investigators. Currently, access is often granted to database
owners only, decreasing the possibility of using routinely
collected data. In some countries, national, local, or regional
data privacy regulations prevent the use of routinely
collected patient-level data and the linkage of information
on individuals between databases such as death or disease
registries. Apart from the data privacy issue, technical chal-
lenges exist, for example, efficient and timely data extraction
from systems can be particularly challenging when data
must be de-identified but the possibility of individual patient
identification needs to be retained for safety reasons. In some
settings, algorithms for probabilistic linking have been
developed to address this [37].4. Opportunities and current developments for the use
of health care databases for pragmatic trials
4.1. International initiatives support the utilization of
health care databases
Several initiatives worldwide are dedicated to improving
both the standardization and quality of routinely collected
data. As routinely collected data were not intended for
research purposes, it is important to create a joint under-
standing on the do’s and don’ts of its collection and use.
Therefore, several guidance documents have been or will
be published to ensure standards and best practices when
using routinely collected data [29,38]. In addition, several
initiatives work on technical solutions for challenges that
arise when using EHRs or other health care databases for
research. Supported by the EU’s 7th Framework
Programme, the TRANSFoRm project aims to develop a
‘‘rapid learning healthcare system’’ that can improve both
patient safety and the conduct and volume of clinical
research in Europe. A dynamic interface is integrated with
EHRs to identify patients eligible for research and collect
outcomes and safety data. Improving the interoperability
of EHR data and other data sources is another aim of
TRANSFoRm [39]. The Electronic Health Records for
Clinical Research (EHR4CR) project of the EU’s Innova-
tive Medicines Initiative developed a technological plat-
form that combines hospital data across countries, with a
focus on the identification of sites and patients for trials
[40]. Another approach to tackle the challenge of heteroge-
neity of multiple sources is being developed in the United
States under the FDA’s Sentinel Initiative, which aimed to
develop a linked system that will draw on existing healthcare data from multiple database sources to actively
monitor the safety of medical products in real time [41].
PCORnet again creates clinical data and patient-powered
research networks to further enhance effectiveness research
[42]. To enhance the quality of EHRs and make their level
of quality more visible, the eClinical consortium will
release a tool under the EHRCR initiative, which will allow
doctors to evaluate the quality and security of their own
EHR systems and provide study teams information on the
quality and content of EHR systems of interest [43].
Achieving homogeneous quality of databases on an inter-
national scale will always be challenging and a formal check
of data quality and completeness will be needed to examine
the suitability of EHR systems or sites for pragmatic trials.4.2. The use of existing registries
A special source of routinely collected data is existing
registries [44]. For the purposes of this article, we define a
registry as any system that collects uniform data [45].
Registries are becoming increasingly common, aiming at
high if not 100% coverage of patients with a target disease
or treatment. If high coverage is achieved, registries may
be considered (public health) surveillance systems. Partici-
pation in a registry is often embedded within clinical prac-
tice either via an additional eCRF or by use of a standard
IT system. If a registry for a specific patient population of
interest exists, it may be particularly suited to a ‘‘nested’’
pragmatic trial or so-called ‘‘registry-based’’ randomized
trial [46e48]. For example, within the TASTE trial, which
is nested within the Swedish Coronary Angiography and
Angioplasty Registry, one out of several registries that run
under the SWEDEHEART registry, all data on end points
were collected through the ‘‘routine registry data collection’’
(Box 4) [47]. This did not just ease patient recruitment and
data collection to a great extent but ultimately reduced the
costs per patient tremendously (50$ per patient) [49]. Regis-
tries may be open to adapting data collection if relevant for
the research objective, especially if also relevant for patient
care. Given that data-collection processes are already in
place within registries, implementing changes may be easier
than setting up a data-collection framework from scratch (eg,
implementing eCRFs). The European PARENT initiative
(cross-border PAtient REgistries iNiTiative) aims to support
the development of comparable and interoperable patient
and disease registries in EU Member States. PARENT is
creating a ‘‘registry of registries,’’ which may soon provide
an overview of the European registry landscape, facilitating
the identification of relevant registries [50].4.3. The use of a hybrid approach
‘‘Hybrid approach’’ means that routinely collected data
are complemented with additional data collected for a spe-
cific study, either through the implementation of additional
IT-solutions to the existing EHR, linking multiple
21A.-K. Meinecke et al. / Journal of Clinical Epidemiology 91 (2017) 13e22databases, collecting patient reported outcomes [51], or by
implementing additional eCRFs [6]. These may be solu-
tions to the challenges that arise when using either eCRFs
or existing medical records solely for data collection,
including the limited availability of certain variables, insuf-
ficient detail, and the timing of data collection but also an
increased interference with routine clinical practice. A
hybrid approach may enable an appropriate data-
collection framework which takes advantage of both worlds
while reducing overall workload. The eLung and Retropro
study are two examples where the implementation of IT
systems within existing EHRs made it possible to flag
eligible patients, efficiently evaluate eligibility, randomize
patients, collect outcome data, and monitor adverse events
(Box 2) [5]. In contrast, the Salford Lung study used near
real-time linkage of primary as well as secondary care elec-
tronic health records next to limited eCRFs for data collec-
tion (Box 3) [6]. The SCOT trial used linkage to national
population health care and mortality databases to ascertain
outcome regarding hospitalizations and a separate eCRF for
adverse events (Box 5) [52].
To integrate additional data, eCRFs or add-on solutions
into an existing system, access to the back-end data of and
IT information pertaining to an EHR or health care data-
base is a prerequisite. The integration of add-on systems
may make additional data entry easier, compared to using
extra eCRFs, and some quality control, for example, using
reminders, might be added while still appropriately reflect-
ing usual care. This could be done, for example, via pop-up
windows, which would have to be completed to be closed,
requesting additional information needed for the trial or re-
minding the GP to schedule follow-up visits [5].5. Conclusions and recommendations
Decisions regarding data collection and management are
important in any clinical trial. When designing pragmatic
trials, it needs to be decided on how much interference with
routine clinical practice through the data-collection process
one is willing to accept to obtain high-quality data. Such
interference should be as limited as possible and as such,
the use of existing EHRs or other routinely used electronic
systems for data collection and management should always
be considered. To determine the feasibility of using stan-
dard systems, one needs to evaluate the process of data en-
try and the level of detail and completeness of the data of
these systems to compare the quality of their data with that
needed for the trial. If an (additional) eCRF-based data-
collection process is chosen, its structure and implementa-
tion should be as easy and as much in line with routine clin-
ical practice as possible. The challenges and possible
solutions identified in this paper should help design teams
to assess both opportunities and limitations in the long list
of potential tools for data collection and management in
their pragmatic trials and to make evidence-based decisions
about the most appropriate method for data collection.Acknowledgments
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